Mexico puts US$46m into HIV/STI centres plan
This article was originally published in Clinica
Mexico has announced plans to invest M$500m (US$46.4m) in 51 ambulatory HIV and sexually-transmitted infection (STI) care and prevention centres. The aim of the CAPASITS (Centro Ambulatorio de Prevencion y Atencion en VIH/SIDA e Infecciones de Transmision Sexual) network is to provide widespread access to HIV/STI services, as well as free treatment for the around 20,000 (of around 180,000) HIV patients who are not insured under Mexico's IMSS, ISSSTE or other social insurance programmes.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.